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Abstract: 
Emerging data from global markets outside the United States, where many generic iron sucrose 
formulations are available, have revealed that non-US generic IV iron formulations may have 
iron release profiles that differ from the reference listed drug (RLD). The first generic IV iron 
approved in the United States was sodium ferric gluconate complex in 2011. We evaluated 
chelatable and redox labile iron assay methods to measure the amount of labile iron released 
from IV iron formulations in biorelevant matrices in vitro. The majority of published labile iron 
assays evaluated were not suitable for use in vitro due to overwhelming interference by the 
presence of the IV iron products. However, an optimized HPLC-based method performed well 
for use in vitro labile iron detection in a biorelevant matrix. Application of this method may 
enhance bioequivalence evaluation of generic IV iron formulations in the future.  
 
Introduction: 
Intravenous (IV) iron products are widely used to treat anemia of various etiologies, 
including chronic kidney disease (CKD), chronic inflammatory disease, heavy uterine bleeding 
and malignancy-related anemia.1 Current commercially available intravenous iron formulations 
consist of an iron oxyhydroxide core surrounded by a carbohydrate shell of various sizes and 
polysaccharide branch characteristics.  These products are formulated as colloidal suspensions 
of nanoparticles.2,3,4 The manufacture of these iron-carbohydrate formulations is sensitive to 
pH, temperature and other conditions in the manufacturing process, presenting challenges to 
reproducible manufacturing of intravenous iron formulations to be considered for generic 
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approval.4 However, it has been shown that complexes of similar molecular weight can be 
synthesized using multiple different manufacturing procedures, suggesting that the iron 
complex may be thermodynamically stable.5  
The available branded IV iron formulations differ with regard to stability profile and 
pharmacokinetic disposition, which directly impacts the rate and extent of labile (i.e. free or 
non-transferrin bound) iron release from the iron-carbohydrate complex.6,7 Emerging data from 
Europe, South America and Asia, where many non-US generic iron sucrose formulations are 
available and in widespread clinical use, have shown that non-US generic IV iron formulations 
may not be therapeutically equivalent and may have increased oxidative stress induction.8,9,10 It 
has been hypothesized that these observations arise due to differences in the stability profile 
and labile iron release from the non-US generic IV iron formulations compared to the reference 
listed drug (RLD).8  
In March 2011, the first generic IV iron, sodium ferric gluconate complex (SFGC) was 
approved in the United States. SFGC was rated AB bioequivalent to Ferrlecit®.11,12 The 
prescribing information (PI) states “Direct movement of iron from sodium ferric gluconate 
complex in sucrose to transferrin was not observed”, however, the methods that support this 
statement were not described.12 The current draft guidance for sodium ferric gluconate 
recommends comprehensive physicochemical characterization of the test and reference products, and 
suggests the possible use of multiple labile iron assessment approaches.13 Identification of a candidate 
assay that is suitable for measurement of labile iron both in vitro and in vivo would facilitate the 
development of an in vitro to in vivo correlation (IVIVC) model to enable prediction of serum 
labile iron in vivo. Such a model could be used to augment physicochemical characterization and 
improve equivalence testing for candidate generic IV iron formulations. The objective of this 
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study was to evaluate redox active and chelatable iron assays for their suitability to measure 
labile iron release from intravenous iron formulations in vitro.  
Materials and Methods: 
Matrices and time points 
To compare labile iron release in vitro, available IV iron formulations; Venofer®, Ferrlecit®, 
generic sodium ferric gluconate complex (NDC 00591-0149-87, Watson Laboratories, Inc), 
InFeD®, Feraheme® and a pre-clinical investigational formulation GE121333 were incubated 
in 150 mM saline and in a bio-relevant matrix (rat serum).14  Rat serum was selected as the 
biorelevant matrix for in vitro labile iron release profiling to optimize comparison of in vitro 
release with in vivo plasma concentration time profiles in this well studied pre-clinical model.8  
Concentrations of 0.95 mg/mL were used to simulate the predicted maximal plasma 
concentration (Cmax) after an intravenous injection of 40 mg/kg of elemental iron in rats from 
each of the six products. The 40 mg/kg dose was selected to limit the need for dilution of the 
agents, which could impact formulation stability and labile iron release profiles.8 To expand the 
chemical classes of agents evaluated, we additionally tested GEH121333, which is a research-
stage iron oxide nanoparticle formulation with a PEG-based coating.14 These samples were 
assayed at frequent pre-specified time points (0,5,15,30,60,90,120 and 150 minutes) using both 
redox active and chelatable iron assay methodologies. Characterization of the rate and extent of 
labile iron release for each formulation as a cumulative consequence of direct, spontaneous 
release from the iron formulation was then evaluated between assays and products. Assays 
were compared by limits of detection (LOD), practical limitations and limitations for in vitro 
performance.  
Labile Iron Measurement: 
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Further detail on assay methods are provided in the supplementary information. 
Redox Active Assays 
Rhodamine Conversion Assay   
In this assay, sodium ascorbate causes labile iron to undergo redox cycling. The resulting 
radicals are detected using dihydrorhodamine (DHR) 123 (non-fluorescent in the absence of 
reactive oxygen species (ROS); catalyzed in the presence of ROS to cationic DHR 123 which 
exhibits a green fluorescence). The addition of an iron-selective chelator (deferiprone) in a 
second reagent solution (solution B) is utilized to assess the specific involvement of labile iron 
which is detected by a quenching of the fluorescent signal. The rate (slope) of DHR fluorescence 
in the presence or absence of the iron chelator is calculated. The procedure was adapted from 
the methods published by Esposito et al.15  
Bleomycin Detectable Iron (BDI) Assay 
Capitalizing on the ability of the chemotherapeutic agent bleomycin to induce oxidative damage 
to deoxyribonucleic acid (DNA) in the presence of ferrous iron (Fe2+), this assay is used to 
indicate the presence of labile iron in an oxidative state capable of catalyzing the generation of 
hydroxyl radicals.  In the originally published methodology for the BDI assay, DNA damage is 
measured by the formation of malondialdehyde (MDA) from the 2’ deoxyribose moiety of DNA 
by the thiobarbituric acid test which measures the resultant TBA-MDA chromophore.16 
Limitations of conventional methods include exposure of the sample to harsh conditions (heat) 
that may induce secondary oxidative stress reactions and detection of byproducts of lipid 
peroxidation other than MDA. These limitations may be avoided through use of a modified 
procedure where DNA damage in the presence of bleomycin, ascorbic acid and iron is 
determined by the fluorescence of the interchelating compound ethidium bromide.16 
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Chelatable Iron Assays 
Desferoxamine Chelatable Iron (DCI) Assay 
Using methodology previously published, this assay detects labile iron utilizing fluoresceinated 
desferoximine (FL-DFO).17 The fluorescence signal of this reagent is stoiciometrically quenched 
in the presence of labile iron. Two reagents (A and B) are prepared to perform the assay. In 
samples treated with Reagent A the labile iron binds to the Fl-DFO present.  The action of iron 
binding to Fl-DFO results in a quenching of the total fluorescence of the compound.  In samples 
treated with Reagent B containing non-fluorescent DFO, labile iron binds the non-fluorescent 
DFO with a higher affinity than the Fl-DFO.  The Reagent B sample is used to correct for non-
iron factors present in the serum that may affect the fluorescence measurement (e.g. turbidity, 
absorbance).  Therefore, the ratio of fluorescence of Reagent A/B is calculated to normalize the 
samples.  The ratio of the fluorescence of Reagent A/B yields a measure of the labile iron 
present in the sample (e.g. ratio ≥ 1 indicates little to no detectable iron in the sample while a 
ratio of 1 indicates the presence of iron).  The ratio of Reagent A/B is inversely proportional to 
the concentration of chelatable labile iron present in the serum sample. 
Fluorescein-conjugated desferoxamine (Fl-DFO) was synthesized following the protocol 
detailed by Su et al.18  
HPLC Detection of Chelatable Iron (HPLC-DFO) 
 
Using methodology adapted from Tesoro et al.19, chelatable iron was detected following 
chelation with 20 mM desferrioxamine (BioVision) and quantified by integration of the colored 
ferioxamine peak following HPLC separation.   
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Results:  
Of the four assays evaluated, only an HPLC-based chelatable iron assay that utilizes 
desferroximine as a chelator (HPLC-DFO) was considered viable for in vitro application. (Table 
1). Although the other three assays demonstrated good performance with ferric chloride 
standard solutions they all exhibited complete and prohibitive interference, when executed in 
the presence of the IV iron formulations themselves.  
For the rhodamine conversion assay the reaction product (cationic rhodamine 123) is 
highly sensitive to ambient conditions and begins to degrade rapidly at the completion of the 
study.  In addition, incubation of the iron agent in the presence of 0.95 mg/mL of Ferrlecit 
produced a near complete attenuation of signal. (Supplementary Information Figure S1) Thus, 
the presence of the IV iron formulation itself produces an interference causing a complete loss 
of detectable signal in the rhodamine conversion assay.  Due to this interference, the rhodamine 
conversion assay is not viable for assessing labile iron in the presence of concentrations 
intended to simulate a predicted Cmax of a 40 mg Fe/kg dose selected for potential application 
to IVIVC modeling.  
When incubated with IV iron formulations, the bleomycin detectable iron (BDI) assay 
reported similar apparent mM levels of labile iron among the IV iron formulations studied.  
However, these findings were also viewed as suspect because of the minimal variation between 
the agents (Figure 1) and because the response was inconsistent with the assessed labile iron 
levels for the agents observed by the other assays in this study, in particular the HPLC-DFO 
assay. To test whether the IV iron formulations interfered with the assay, an experiment was 
conducted using single stranded DNA consisting of two test groups: 5-500 µM Iron (III) Chloride 
and 5-500 µM Iron (III) Chloride in the presence of 0.95 mg/mL of Ferrlecit.  As seen in Figure 2, 
incubation of iron in the presence of a 40 mg/kg equivalent of Ferrlecit® produces a significant 
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attenuation of the percent fluorescence.  Furthermore, this effect was seen in the reaction tube 
and not the 0% and 100% fluorescence control samples showing that the attenuating effect of 
the IV iron formulations in this assay is a result of a direct effect of the formulations on the 
bleomycin reaction responsible for DNA degradation causing effects on fluorescence output of 
the assay.  While the mechanistic nature of this interfering reaction was not studied, the BDI 
assay is therefore shown to not be suitable for measurements of samples in which unknown 
concentrations of IV iron formulations may be present.  
Calibration of the DCI Assay was performed with Iron (III) Chloride Hexahydrate. No 
significant change in fluorescence of samples treated with Reagent A was seen in concentrations 
greater than 64.6 µM or less than 1.5 µM.  Furthermore, samples treated with Reagent B showed 
no decrease in fluorescence intensity at concentrations 500 µM. (Supplemental Information 
Figure S2) However, a significant reduction in Reagent B fluorescence occurred following 
incubation of IV iron formulations in serum and in PBS samples.  While these findings suggest a 
significant interference, an interaction of the IV iron formulation with a serum component is 
unlikely as a similar effect was seen in both PBS and fresh rat serum.  A possible explanation is 
the presence of large amounts of labile iron in IV iron formulation incubated samples, which 
quickly saturates the non-fluorescent DFO present in Reagent B.  To test this, we increased the 
non-fluorescent DFO five fold in Reagent B; however, no effect was observed on the apparent 
inhibition of fluorescence, suggesting this is not due to labile iron in excess of the unlabeled DFO 
pool in Reagent B.  Therefore, these experiments strongly suggest an interaction between the Fl-
DFO and the IV iron formulation is capable of quenching Fl-DFO fluorescence, making 
impossible the measurement of labile iron in the presence of the IV iron formulation.  Optical 
absorbance by the IV iron formulation at the measured wavelengths (485nm) may be an 
additional factor in the interference. These findings demonstrate that the DCI assay is not 
suitable for in vitro samples containing IV iron formulations, and provided the stimulus for 
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application of an HPLC separation method to avoid readout interferences caused by the 
presence of the iron formulations. 
Representative HPLC-DFO response curves for FeCl3 in saline and in rat serum are 
shown in Figure 3. This assay as implemented also demonstrated the greatest assay dynamic 
range (~50 µM to at least 2 mM) of the assays tested in this study. The assay was not optimized 
in this work to minimize the LOD given that the labile iron of the agent samples in this study 
were in the hundreds of µM range; indeed a sub-µM LOD has been reported for a similarly 
implemented assay showing further improvement in LOD may be possible.20 However, the LOD 
was routinely achievable and more than sufficient for the scope of work described. Accuracy of 
the HPLC-DFO assay was assessed in several ways.  First, the calibration standards were run in 
triplicate to allow determination of the coefficient of variance (CV, as the ratio of SD to mean) as 
a function of iron concentration after collection of each calibration curve.  Typically, in both 
saline and serum, the CV was less than ~2% for iron standard concentrations greater than 500  
µM.  Between 100 and 500 µM, the CVs were typically <10%.  At and below the LOD (~50 µM), 
the CVs increased to ~50-100%.  As a second assessment of accuracy and repeatability, a one-
time experiment tested repeated measures of a 500 µM spike sample in rat serum.  For 12 
repeated measures over two days, the average measured was 491±33 µM (µ±SD) for a recovery 
of 98.3% and a CV of 6.7%.  There was no apparent trend in these repeated measures over the 
course of the experiment, suggesting that kinetic effects following incubation of free iron with 
DFO are negligible.   
 When the IV iron formulations were tested, each showed an increase in Fe-DFO peak 
area as a function of incubation time in the presence of DFO. A similar, time-dependent increase 
in Fe-DFO signal was not observed after a 3 h incubation at ambient temperature when FeCl3 
was used as the iron source.  Thus, it was hypothesized that the continuing increase in Fe-DFO 
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peak area as a function of incubation time was due to a kinetic release of labile iron from the IV 
iron formulations.   
To test this hypothesis, IV iron formulations were diluted as described above into either 
saline or serum and incubated at ambient temperature for either 15 or 180 minutes in the 
absence of DFO. (Figure 4A and 4B)  Once this initial pre-incubation was complete, DFO was 
then added and the resulting solutions were repeatedly analyzed by HPLC at longitudinal time 
points.  The resulting natural logarithm transformed labile iron concentrations versus time data 
were fit by linear regression. (Figure 4A and 4B) This regression permitted estimation of the 
concentration of labile Fe at t = 0 (y-intercept) because it is not technically feasible to 
instantaneously measure the labile iron for each IV iron formulation present upon addition of 
DFO (t = 0). (Table 2) Incubation of the IV iron formulations in saline or serum for 15 or 180 
minutes allowed for identification of kinetic release of iron in the absence of DFO in either 
medium. Our results show that there is negligible difference between the fits for the solutions 
incubated for either 15 or 180 min prior to the addition of DFO for all agents tested.(Figure 4A 
and 4B) The absence of differences at t = 0 suggests that additional iron is not released by any of 
the commercial IV iron formulations in the absence of DFO chelator for the conditions tested 
here (i.e., 0.95 mg/mL agent concentration, tested over a 3 hour time frame).  While the data for 
GEH121333 in saline suggests there may be an increase in the chelatable Fe concentration, the 
difference in the linear fits as a function of incubation time prior to DFO addition is likely due to 
the non-linearity of the labile iron concentration at < 3 hours incubation times with DFO (Figure 
4A).  While the reason for the observed non-linearity is not known for GEH121333, exclusion of 
the data for the < 3 hour time points as recommended yields little if any difference as a function 
of incubation time and suggests that additional iron is not released following dilution into 150 
mM saline on the time scale studied. A similar analysis was also conducted following dilution of 
the IV iron formulations in rat serum. Similar to the results described above, little to no 
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difference was observed at t = 0 as a function of incubation time without DFO, suggesting the 
absence of a kinetic release upon incubation in serum for up to 3 hours. (Figure 4B) Thus, the 
HPLC-DFO assay does not exhibit any apparent issues with interference from IV iron 
formulations in vitro. 
Discussion:  
Clinical use of IV iron colloidal suspension formulations began in the late 1950’s, which 
preceded the nanomedicine exploration frontier.4 Considering the rising use of IV iron 
formulations for a number of chronic diseases in the context of a cost constrained health care 
environment, it is reasonable to speculate that use of generic IV iron formulations will increase 
as they become available.1  The complexity of IV iron formulations differentiates them from 
traditional small molecules and as such they have been described as “non-biologic complex 
drugs” by non-US regulatory groups.21 Based on experience from generic formulations outside 
US,  creating an exact copy of the RLD is challenging.4 Thus, it is important to improve and 
sophisticate analyses to evaluate abbreviated new drug applications (ANDAs) for these 
products. 
The relevance of potential reduced stability profiles of generic IV iron formulations is 
related to formulation-based labile iron release after administration. Among available IV iron 
formulations, products with smaller particle sizes are more labile and more likely to release 
labile iron directly into the plasma (i.e. before metabolism by RES).6 We observed that the 
smallest molecular weight formulations (Ferrlecit® and SFGC) had higher labile iron release 
profiles in vitro.   The hypothesis for the pathogenesis of acute oxidative stress induced by 
intravenous iron formulations is the direct release of iron from the iron-carbohydrate structure 
resulting in transient concentrations of labile plasma iron. Labile iron can participate in Fenton 
chemistry and the Haber-Weiss reaction promoting formation of highly reactive free radicals 
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such as the hydroxyl radical.22 The proposed biologic targets of labile-iron-induced oxidative 
stress may include systemic cellular components including endothelial cells, myocardium, liver 
as well as low density lipoprotein and other plasma proteins. An additional concern regarding 
appearance of labile plasma iron is the potential for easily accessible iron to augment bacterial 
growth and increase the risk of infection.23  
As we have investigated and confirmed in our in vitro analyses in a biorelevant matrix 
(rat serum), labile iron release profiles differ among available IV iron formulations.  We have 
shown that the measured labile iron concentrations for most formulations was notably lower in 
the rat serum matrix versus saline, with the lone exception being Feraheme®.  Spike recovery 
data presented show that recovery of free iron in serum is complete for our assay conditions, 
suggesting that these observed reductions in measured labile iron in serum may be a result of 
stabilization of the colloidal dispersions by the presence of serum proteins.  It is important to 
acknowledge that although some non-US generic IV iron formulations may not be differentiable 
based on certain physicochemical characteristics and may have met Pharmacopeia criteria, they 
may potentially nonetheless still appear to exhibit differential toxicity profiles in vivo.8,9 Thus, it 
is important to establish comprehensive physicochemical characterization including labile iron 
release and the existing data in the literature considered in tandem with an IVIVC model would 
be useful to further inform bioequivalence of IV iron formulations filing ANDAs.  
In our analyses, the HPLC-DFO chelatable labile iron assay performed better than the 
other assays when tested at higher concentrations of IV iron formulations, and provided the 
widest dynamic range of the assays tested. Addition of the HPLC-based separation step in this 
new assay format eliminates potential confounding of response by presence of the 
nanoparticulate iron formulations and/or media components that are otherwise present in 
previously reported incubate-and-read DFO chelation assay formats.  Labile iron concentrations 
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were detected by the bleomycin detectable iron assay in vitro, however, interference in the 
presence of the agents is problematic. Other studies have used the bleomycin detectable iron 
assay to determine labile iron concentrations in ex vivo spiked rat serum samples.7 However, 
the doses utilized in those experiments were much lower and necessitated a several fold 
dilution that is far greater than what is recommended by the prescribing information. This can 
compromise the stability of the IV iron formulation.24 Although typical clinical intravenous push 
doses for the various IV iron formulations range from 2 to 15 mg/kg, this would require 
substantial dilution for in vitro analysis and would not be representative of the formulations 
stability profile when administered to patients undiluted by intravenous push.25,26 Our approach 
to the doses used in this study minimized the need for dilution and would be sufficient to 
determine a release profile in vivo over time.  The rhodamine fluorescence conversion and 
fluorescence-based directly chelatable iron assays were determined not to be viable for in vitro 
analysis due to reduced or no signal in the presence of high concentrations of the IV iron 
formulations. Among four assays evaluated to detect labile iron in vitro, the HPLC-based DFO 
chelatable iron assay was considered most viable for potential use to evaluate comparative 
labile iron release from IV iron formulations.  
There are several limitations of the current study.  Our evaluation of available in vitro 
labile iron assays may not have been exhaustive, and in particular we considered evaluating an 
additional reported chelatable iron assay utilizing the metalosensor calcein27 to detect labile 
iron. However, this assay could not be tested as part of this study because the key reagent a 
calcein-iron complex is no longer available commercially. An additional limitation is that we 
only examined single lot of each product studied. There have been data suggesting lot-to-lot 
variations in physicochemical characteristics and emergence of clinical adverse events.8,23 The 
only FDA approved generic product (SFGC) was studied in this series of experiments. It would 
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be advantageous to test other non-US generic IV iron formulations available in the global 
market to further evaluate in vitro labile iron release and to inform further IVIVC development. 
In summary, published assay methodologies to detect labile iron have limitations with 
regard to equivalence evaluation of RLD and generic products. This necessitates additional 
evaluation of these formulations in bio-relevant matrices in vitro and in vivo. This is the first 
study to evaluate all of the commercially available IV iron formulations including the only FDA-
approved generic product to quantitate labile iron release in vitro. We determined that an 
HPLC-DFO chelatable labile iron assay performed optimally in vitro with relevant 
concentrations of IV iron formulations diluted in rat serum designed to simulate maximal 
plasma concentrations in vivo. This assay also provided the widest dynamic range of the assays 
tested. Thus, future IVIVC modeling efforts will benefit from using this new assay approach to 
compare labile iron release from IV iron formulations in vitro. 
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Study Highlights  
What is the current knowledge on the topic? Studies have identified safety issues with 
labile iron release from iron formulations but translation to bioequivalence evaluation has 
not been studied. What question did this study address? Currently, there have been no 
published studies systematically evaluating the various labile iron assays for potential 
in vitro application to enhance current bioequivalence regulatory guidance. What this 
study adds to our knowledge. This study evaluated four assays, two based on chelation 
methodology and two based on redox methodology for use in vitro. We found that of the 
  
 
This article is protected by copyright. All rights reserved. 
 
17 
assays studied only an HPLC assay based on chelation with desferroximine was viable 
for in vitro use. How this might change clinical pharmacology or translational science? 
Further study of this assay method in vivo may inform an in vitro in vivo correlation 
model to augment bioequivalence requirements for generic intravenous iron 
formulations. 
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Figure 1. BDI assay calibration and agents.  A representative calibration curve generated 
using 2 mg/mL DNA in PBS at 37 C is shown (blue diamonds) for iron(III) chloride standards 
ranging in concentration from 20 µM to 1 mM.  Example readings of the 6 agents are also shown 
for IV iron formulations as labeled at concentrations of 0.95 mg Fe/mL. 
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Figure 2. BDI Assay in presence and absence of Ferrlecit®.  Incubation of iron (III) 
chloride in the absence of Ferrlecit (blue) as compared to incubation in the presence of 
0.095 mg/mL and 0.95 mg/mL concentrations of Ferrlecit.  An attenuation of 
fluorescence signal attributable to labile iron is observed with increasing Ferrlecit agent 
concentration, suggesting assay interference.   
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Figure 3. Representative Fe-DFO HPLC response curves for FeCl3 in saline and in rat 
serum. Plots of the Fe-DFO peak area at 427 nm following triplicate HPLC analysis vs. input iron 
concentration were linear with R2 > 0.999 and were comparable for 150 mM saline and for rat 
serum. Red lines represent 95% confidence intervals of iron concentration for given HPLC 
response measurement, and the red plus represents the limit of detection for the calibration 
(both shown only for saline for clarity; similar CIs and LOD were determined for serum).  The 
linear regression equations for saline was 427 nm peak area = 1620([Fe] (µM)) + 65595 with an 
R2 = 0.9994, and for rat serum was 427 nm peak area = 1699([Fe] (µM)) + 99610 with an R2 = 
0.9996.  The subtle difference in the calibration line slope is likely attributable to HPLC 
performance differences over a period of months between collection of these examples; 
standard calibration curves were generated concurrently for use with every run of sample 
batches.   
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Figures 4A and 4B. Natural logarithm of the Fe-DFO peak area as a function of time 
following addition of DFO and linear regression analyses for IV iron formulations (0.952 
mg/mL) incubated in 150 mM saline (A) or rat serum (B) for 15 or 180 minutes prior to 
the addition of DFO. 
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Figure 5. Representative HPLC chromatogram at 427 nm.  The peak at 3.9 min is the 
Fe-DFO chelate. 
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Table 1. Summary of Labile Iron Assays Evaluated in vitro 
Labile Iron 
Assay 
Assay Method  Approximate 
LOD* 
Practical 
limitations 
In vitro 
limitations 
Rhodamine 
fluorescence 
Conversion 
Redox active 
iron 
30 µM Fe Reaction 
product is very 
sensitive in 
ambient 
conditions and 
degrades 
rapidly. 
Abolished signal 
in the presence 
of agent 
complex.  
Bleomycin 
detectable iron 
(BDI) 
Redox active 
iron 
10 µM Fe Multiple 
reagents and 
pipetting steps 
required may 
reduce 
accuracy.  
Narrow assay 
dynamic range 
(10-100µM). 
Strong 
interference in 
the presence of 
agent complex.    
Directly 
chelatable iron 
(DCI): FL-DFO 
Chelatable iron 2 µM Fe Narrow assay 
dynamic range 
(~2-~60µM).  
Abolished 
fluorescence in 
the presence of 
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agent complex 
HPLC-DFO Chelatable iron 50 µM Fe** Duration to 
complete 
analysis 
Apparent 
kinetic increase 
of labile iron 
upon incubation 
with DFO when 
agents are 
present 
(correctable 
using kinetic 
analysis to 
back-calculate 
labile iron at 
t=0). 
*The assay limit of detection (LOD) as employed was estimated in y as the intercept plus 3 times 
the standard error of the fit. 
**Routinely achievable, sufficient for scope of work 
 
 
 
 
Table 2. Chelatable iron concentrations following pre-incubation in either 150 mM saline 
or rat serum.  
 
IV iron 
formulation 
Pre-
incubation 
time* 
150 mM saline rat serum 
[chelatable 
Fe] (µM) 
± 95% CI [chelatable 
Fe] (µM) 
± 95% CI 
Ferrlecit 15 min 959 120 595 23 
180 min 756 42 514 27 
SFG Complex 15 min 616 17 411 19 
180 min 549 15 378 15 
INFeD 15 min 801 46 155 11 
180 min 835 29 151 8 
Venofer 15 min 392 33 138 23 
180 min 397 18 80 4 
Feraheme 15 min 220 13 278 24 
180 min 236 18 268 21 
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GEH121333 15 min 347 82 174 8 
180 min 531 43 148 7 
*Iron concentrations were determined using the calculated Fe-DFO peak area at t = 0 
from linear regression of the Fe-DFO peak area as a function of time following addition 
of DFO. 
 
 
 
